Page last updated: 2024-12-11

brl 26830a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BRL 26830A: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438331
MeSH IDM0117628

Synonyms (6)

Synonym
87857-42-9
methyl 4-(2-((2-hydroxy-2-phenethyl)amino)propyl)benzoate-2-butanedioate
benzoic acid, 4-(2-((2-hydroxy-2-phenylethyl)amino)propyl)-, methyl ester, (r*,r*)-(+-)-, (e)-2-butenedioate (2:1) (salt)
brl 26830a
brl 26830
methyl 4-[(2s)-2-[[(2s)-2-hydroxy-2-phenylethyl]amino]propyl]benzoate;(e)-4-oxopent-2-enoic acid

Research Excerpts

Overview

BRL 26830A is a beta-adrenoceptor agonist drug that shows a high degree of selectivity for thermogenesis. It has potential as an antiobesity agent.

ExcerptReferenceRelevance
"BRL 26830A is a beta-adrenoceptor agonist drug that shows a high degree of selectivity for thermogenesis and has potential as an antiobesity agent. "( Clinical studies with the beta-adrenoceptor agonist BRL 26830A.
Bennet, WM; Connacher, AA; Jung, RT, 1992
)
1.98
"BRL 26830A is a thermogenic beta-adrenergic agonist drug which has an anti-obesity effect in animals and diet-restricted obese man. "( Metabolic effects of three weeks administration of the beta-adrenoceptor agonist BRL 26830A.
Bennet, WM; Connacher, AA; Jung, RT; Rennie, MJ, 1992
)
1.95

Effects

BRL 26830A has thermogenic activity and it is suggested that this might be linked to increased glucose utilization. It has been evaluated in man with conflicting results.

ExcerptReferenceRelevance
"BRL 26830A has thermogenic activity and it is suggested that this might be linked to increased glucose utilization."( Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes.
Carroll, MJ; Cawthorne, MA; Levy, AL; Lister, CA; Sennitt, MV; Smith, SA; Young, P, 1984
)
0.99
"BRL 26830A has been evaluated in man with conflicting results."( Pharmacological approaches to the regulation of fat metabolism.
Chapman, BJ; Munro, JF; Stewart, IC, 1986
)
0.99

Treatment

Treatment with BRL 26830A increased the glycolytic capacity 10-fold. Treatment did not modify Glut 4 in skeletal muscle, and it increased Glut4 number in white adipose tissue.

ExcerptReferenceRelevance
"BRL 26830A treatment did not modify Glut 4 in skeletal muscle, and it increased Glut 4 number in white adipose tissue in a dose-dependent manner."( Glucose transporter in insulin sensitive tissues of lean and obese mice. Effect of the thermogenic agent BRL 26830A.
Grémeaux, T; Le Marchand-Brustel, Y; Olichon-Berthe, C; Rochet, N; Tanti, JF; Van Obberghen, E, 1990
)
1.21
"Treatment with BRL 26830A increased the glycolytic capacity 10-fold."( Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes.
Carroll, MJ; Cawthorne, MA; Levy, AL; Lister, CA; Sennitt, MV; Smith, SA; Young, P, 1984
)
0.61

Dosage Studied

The energy content of this lipid lost during the 4-h period after dosing was equivalent to approximately 50% of the thermogenic effect of the compound over the same period. Lipid stored in brown adipose tissue is a major initial fuel for BRL 26830A induced thermogenesis. Exposure of obese animals to cold increased the level of uncoupling protein mRNA.

ExcerptRelevanceReference
" The energy content of this lipid lost during the 4-h period after dosing was equivalent to approximately 50% of the thermogenic effect of the compound over the same period, suggesting that lipid stored in brown adipose tissue is a major initial fuel for BRL 26830A induced thermogenesis."( Substrate supply for thermogenesis induced by the beta-adrenoceptor agonist BRL 26830A.
Arch, JR; Thurlby, PL; Wilson, S, 1987
)
0.68
" At 1 h after dosing with BRL 26830A, mitochondrial GDP binding was increased more than 2-fold."( Acute effects of a beta-adrenoceptor agonist (BRL 26830A) on rat brown-adipose-tissue mitochondria. Increased GDP binding and GDP-sensitive proton conductance without changes in the concentration of uncoupling protein.
Arch, JR; Milner, RE; Trayhurn, P; Wilson, S, 1988
)
0.83
" Moreover, exposure of obese animals to cold or dosing with BRL 26830A strikingly increased the level of uncoupling protein mRNA."( Expression of uncoupling protein mRNA in thermogenic or weakly thermogenic brown adipose tissue. Evidence for a rapid beta-adrenoreceptor-mediated and transcriptionally regulated step during activation of thermogenesis.
Arch, J; Bazin, R; Bouillaud, F; Mory, G; Pénicaud, L; Ricquier, D; Toumelin, P, 1986
)
0.51
" Repeat dosing caused hypertrophy of brown adipose tissue and improved cold tolerance in mice."( Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.
Ainsworth, AT; Arch, JR; Ellis, RD; Piercy, V; Thody, VE; Thurlby, PL; Wilson, C; Wilson, S; Young, P, 1984
)
0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (53.85)18.7374
1990's16 (41.03)18.2507
2000's2 (5.13)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.30 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.10 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (12.82%)5.53%
Reviews3 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (79.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]